Literature DB >> 32926175

Management of Ocular Manifestations of Atopic Dermatitis: A Consensus Meeting Using a Modified Delphi Process.

Jacob P Thyssen1, Steffen Heegaard, Lena Ivert, Anita Remitz, Tove Agner, Marjolein De Bruin-Weller, Theis Huldt-Nystrøm, Laura Korhonen, Lina U Ivert, Pekka Leinonen, Johanna Mandelin, Tore Särnhult, Thomas Schopf, Eirik Sundlisæter, Simon F Thomsen, Thrasyvoulos Tzellos, Christian Vestergaard, Laura von Kobyletzki, Maria Bradley.   

Abstract

There is a need for unified guidance on the management of ocular manifestations of atopic dermatitis and ocular manifestations associated with dupilumab in the Nordic region (Denmark, Finland, Norway and Sweden). This initiative gathered Nordic dermatologists and ophthalmologists to identify consensus in this area using a modified Delphi process. The initiative was led by a Nordic expert panel who developed a questionnaire that was circulated to a wider group. The results informed an agenda consisting of 24 statements to be voted on using a 5-point Likert scale at a meeting in Copenhagen on 24 April 2019. A facilitator moderated discussion and revised statements according to expert feedback for a second vote when required to reach consensus. Consensus was reached for 23 statements regarding the diagnosis, treatment and referral of these patients, which we hope will improve patient management in the Nordic region.

Entities:  

Keywords:  consensus; modified Delphi process; ocular manifestation; atopic dermatitis

Mesh:

Year:  2020        PMID: 32926175      PMCID: PMC9235002          DOI: 10.2340/00015555-3629

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   3.875


  27 in total

Review 1.  Atopic dermatitis and keratoconjunctivitis.

Authors:  Brett Bielory; Leonard Bielory
Journal:  Immunol Allergy Clin North Am       Date:  2010-08       Impact factor: 3.479

2.  Eye Complications During Dupilumab Treatment for Severe Atopic Dermatitis.

Authors:  Lina U Ivert; Carl-Fredrik Wahlgren; Lena Ivert; Maria Lundqvist; Maria Bradley
Journal:  Acta Derm Venereol       Date:  2019-04-01       Impact factor: 4.437

3.  Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma.

Authors:  Klaus F Rabe; Parameswaran Nair; Guy Brusselle; Jorge F Maspero; Mario Castro; Lawrence Sher; Hongjie Zhu; Jennifer D Hamilton; Brian N Swanson; Asif Khan; Jingdong Chao; Heribert Staudinger; Gianluca Pirozzi; Christian Antoni; Nikhil Amin; Marcella Ruddy; Bolanle Akinlade; Neil M H Graham; Neil Stahl; George D Yancopoulos; Ariel Teper
Journal:  N Engl J Med       Date:  2018-05-21       Impact factor: 91.245

4.  Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry.

Authors:  Lieneke F M Ariëns; Jorien van der Schaft; Daphne S Bakker; Deepak Balak; Margreet L E Romeijn; Tessa Kouwenhoven; Marijke Kamsteeg; Barbara Giovannone; Julia Drylewicz; Cynthia Catalina Aurora van Amerongen; Evelien M Delemarre; Edward F Knol; Femke van Wijk; Stefan Nierkens; Judith L Thijs; Marie L A Schuttelaar; Marjolein S de Bruin-Weller
Journal:  Allergy       Date:  2019-10-31       Impact factor: 13.146

5.  Th2 Cytokines and Atopic Dermatitis.

Authors:  Eric B Brandt; Umasundari Sivaprasad
Journal:  J Clin Cell Immunol       Date:  2011-08-10

6.  Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population-based study.

Authors:  Jonathan I Silverberg; Jon M Hanifin
Journal:  J Allergy Clin Immunol       Date:  2013-10-04       Impact factor: 10.793

Review 7.  Epidemiology of atopic dermatitis: a review.

Authors:  Sigrid Payne DaVeiga
Journal:  Allergy Asthma Proc       Date:  2012 May-Jun       Impact factor: 2.587

8.  Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis.

Authors:  Julia K Gittler; Avner Shemer; Mayte Suárez-Fariñas; Judilyn Fuentes-Duculan; Kara J Gulewicz; Claire Q F Wang; Hiroshi Mitsui; Irma Cardinale; Cristina de Guzman Strong; James G Krueger; Emma Guttman-Yassky
Journal:  J Allergy Clin Immunol       Date:  2012-08-27       Impact factor: 10.793

9.  Conjunctivitis in dupilumab clinical trials.

Authors:  B Akinlade; E Guttman-Yassky; M de Bruin-Weller; E L Simpson; A Blauvelt; M J Cork; E Prens; P Asbell; E Akpek; J Corren; C Bachert; I Hirano; J Weyne; A Korotzer; Z Chen; T Hultsch; X Zhu; J D Davis; L Mannent; J D Hamilton; A Teper; H Staudinger; E Rizova; G Pirozzi; N M H Graham; B Shumel; M Ardeleanu; A Wollenberg
Journal:  Br J Dermatol       Date:  2019-05-07       Impact factor: 9.302

10.  Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis.

Authors:  D S Bakker; L F M Ariens; C van Luijk; J van der Schaft; J L Thijs; M L A Schuttelaar; F van Wijk; E F Knol; D M W Balak; M R van Dijk; M S de Bruin-Weller
Journal:  Br J Dermatol       Date:  2019-02-04       Impact factor: 9.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.